Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide.
BACKGROUND
Genital herpes (GH) is a recurrent sexually transmitted infection (STI) that causes significant morbidity and is also the major source of herpes simplex virus (HSV) in cases of neonatal herpes. Vaccination is a current goal which has had limited success so far in preventing GH and microbicides offer an attractive alternative. Treatment of primary disease cannot prevent establishment of latent infections and thus, cannot prevent subsequent recurrent disease. Recently, many of the molecular events leading to entry of HSV into cells have been elucidated, resulting in the description of a number of herpesvirus entry mediators (HVEMs) that interact with HSV glycoprotein D (gD) on the surface of virions. Described here is a strategy for interrupting the spread of HSV based on interfering with these interactions. The hypothesis addressed in the current report was that single chain antibody variable fragments (scFv) that interrupt associations between gD and HVEMs would not only prevent infection in vitro but could also be used as microbicides to interfere with acquisition GH.


CONCLUSIONS
Here we show that a scFv derived from a particular hybridoma, DL11, not only inhibits infection in vitro but also prevents development of GH in a guinea pig model when applied intravaginally in an inert vehicle. Comparison of different anti-gD single chain antibodies supported the hypothesis that the activity of DL11-scFv is based on its ability to disrupt the associations between gD and the two major receptors for HSV, nectin-1 and HveA. Further, the results predict that bacterial expression of active single chain antibodies can be optimized to manufacture inexpensively a useful microbicidal product active against HSV.
Chen
Jianmin
J
University of Texas Medical Branch, Galveston, Texas, USA. jiachen@utmb.edu
Davé
Sanat K
SK
Simmons
Anthony
A
D000818:Animals; D000914:Antibodies, Viral / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000276:immunology; D018258:Herpesvirus 2, Human / Q000276:immunology; D010865:Pilot Projects; D011487:Protein Conformation; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; C039447:glycoprotein D, Human herpesvirus 1